Controlled antithrombotic prevention of oncothrombosis: dinical economic analysis

Efficacy of nonfractionated heparin (NH) and low molecular weight heparin (PMWH), fragmin, for prevention of postoperative thrombosis was evaluated in prospective randomized study and clinical economic analysis was carried out. A total of 102 patients operated on for visceral cancer were divided into 2 groups. The level of soluble fibrin in blood plasma was used as an efficacy criterion. The level of soluble fibrin in postoperative period was significantly reduced in patients who received fragmin. Expenses for medicine and blood preparations per a patient within the treatment period were statistically less significant using NH than fragmin (average 2849.4 roubles versus 6066.4 roubles, p=0.0001). No significant differences in total treatment costs between two groups were observed but medical service costs were less with fragmin than with NH (average 21770.0 roubles and 19765.0 roubles, p=0.012). Antithrombotic prevention with fragmin as compared to NH was characterized by lower expenses for reduction in the level of soluble fibrin per 1 mg % (average 3509.2 roubles versus 8189.1 roubles).